相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene
Mohammad-Nazir Menbari et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Local anesthetics counteract cell proliferation and migration of human triple-negative breast cancer and melanoma cells
Vanessa Castelli et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
Afshin Derakhshani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Mn(II) complex of a vitamin B6 Schiff base as an exclusive apoptosis inducer in human MCF7 and HepG2 cancer cells: Synthesis, characterization, and biological studies
Zohreh S. Tabatabayi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2020)
Ganoderma lucidum spore oil induces apoptosis of breast cancer cells in vitro and in vivo by activating caspase-3 and caspase-9
Chunwei Jiao et al.
JOURNAL OF ETHNOPHARMACOLOGY (2020)
In-vitro and in-vivo anti-breast cancer activity of OEO (Oliveria decumbens vent essential oil) through promoting the apoptosis and immunomodulatory effects
Tahereh Jamali et al.
JOURNAL OF ETHNOPHARMACOLOGY (2020)
miR-216a promotes breast cancer cell apoptosis by targeting PKCα
Ying Cui et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2019)
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Jason J. Zoeller et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
Elmira Ekinci et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2019)
Association of caspase 8 promoter variants and haplotypes with the risk of breast cancer and its molecular profile in an Iranian population: A case-control study
Matineh Barati Bagherabad et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR-33a-5p-LDHA axis
Xiangdong Bai et al.
MOLECULAR MEDICINE REPORTS (2019)
C/EBPε ΔRS derived from a neutrophil-specific granule deficiency patient interacts with HDAC1 and its dysfunction is restored by trichostatin A
Masahiro Muraoka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
BODIPY-Caged Photoactivated Inhibitors of Cathepsin B Flip the Light Switch on Cancer Cell Apoptosis
Nicholas P. Toupin et al.
ACS CHEMICAL BIOLOGY (2019)
The ATG5-binding and coiled coil domains of ATG16L1 maintain autophagy and tissue homeostasis in mice independently of the WD domain required for LC3-associated phagocytosis
Shashank Rai et al.
AUTOPHAGY (2019)
Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1
Yanyan Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
Yoshimi Endo Greer et al.
BREAST CANCER RESEARCH (2019)
Extracellular vesicles and anti-cancer drug resistance
Niamh Mc Namee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings
Shengpeng Wang et al.
FOOD AND CHEMICAL TOXICOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
Sonia Palomeras et al.
MOLECULES (2018)
Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (vol 34, pg 1919, 2015)
D. Elias et al.
ONCOGENE (2018)
3-Bromopyruvate sensitizes human breast cancer cells to TRAIL-induced apoptosis via the phosphorylated AMPK-mediated upregulation of DR5
Yuzhong Chen et al.
ONCOLOGY REPORTS (2018)
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
Damien Cote et al.
PLOS ONE (2018)
LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications
Yoo Jane Han et al.
SCIENTIFIC REPORTS (2018)
LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
Ang Gao et al.
NATURE COMMUNICATIONS (2018)
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
Khaldoun Rifai et al.
CANCERS (2018)
ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes
Aurore Claude-Taupin et al.
CELLS (2018)
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
Qingyuan Zhang et al.
CHINESE JOURNAL OF CANCER RESEARCH (2018)
Autophagy in cancer metastasis
E. E. Mowers et al.
ONCOGENE (2017)
Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1α pathway and generation of reactive oxygen species
Hongyu Zhang et al.
ONCOTARGET (2017)
ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy
Martina Antonelli et al.
ONCOTARGET (2017)
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells
Yin Li et al.
CLINICAL EPIGENETICS (2017)
Breast Cancer: Current Molecular Therapeutic Targets and New Players
Siddavaram Nagini
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2017)
TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA
Han Han et al.
CELL DEATH DISCOVERY (2017)
Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis
Hyung Sik Kim et al.
ARCHIVES OF TOXICOLOGY (2016)
Opposing roles of TGF-β and EGF in the regulation of TRAIL-induced apoptosis in human breast epithelial cells
Ana Cano-Gonzalez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Aberrant methylation of ATG2B, ATG4D, ATG9A and ATG9B CpG island promoter is associated with decreased mRNA expression in sporadic breast carcinoma
Xuemei Zhang et al.
GENE (2016)
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Andrew P. Feinberg et al.
NATURE REVIEWS GENETICS (2016)
Identification of breast cancer cell subtypes sensitive to ATG4B inhibition
Svetlana Bortnik et al.
ONCOTARGET (2016)
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells
Weiqiang Zhou et al.
SCIENTIFIC REPORTS (2016)
MTOR, PIK3C3, and autophagy: Signaling the beginning from the end
Michael J. Munson et al.
AUTOPHAGY (2015)
Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer
Lan Zhang et al.
MOLECULAR BIOSYSTEMS (2015)
Trailing TRAIL resistance: novel a gets for TRAIL sensitization in cancer cells
Rachana Trivedi et al.
FRONTIERS IN ONCOLOGY (2015)
A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype
Jonas Wolf et al.
BREAST CANCER RESEARCH (2013)
Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID?
Victoria C. Hodgkinson et al.
JOURNAL OF PROTEOMICS (2012)
Is there any correlation between TNF-related adoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?
Yemliha Yildiz et al.
ARCHIVES OF MEDICAL SCIENCE (2010)
TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells
Griselda Herrero-Martin et al.
EMBO JOURNAL (2009)
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
Sharmila Shankar et al.
MOLECULAR CANCER THERAPEUTICS (2009)